Potensi Kadar Neopterin sebagai Biomarker untuk Monitoring Kemajuan Terapi TB Paru pada Anak
DOI:
https://doi.org/10.21776/ub.jkb.2013.027.04.7Abstract
Kadar neopterin plasma ditemukan berhubungan dengan efikasi terapi pada tuberkulosis paru pasien dewasa. Penanda biologis untuk diagnosis tuberkulosis pada anak masih terus diteliti. Penelitian ini dilakukan untuk mengidentifikasi peran neopterin sebagai penanda biologis untuk mengevaluasi keberhasilan terapi standar tuberkulosis paru pada anak. Sebanyak 25 pasien dengan tuberkulosis paru diikuti selama enam bukan. Kadar neopterin plasma diukur dengan metode ELISA sebelum terapi, 2, 4, dan 6 bulan sesudah terapi. Sepuluh anak sehat ditetapkan sebagai kontrol. Hasil menunjukkan pada semua pasien kadar neopterin tertinggi didapatkan sebelum terapi dengan rerata 0,27 (SD 0,09c ) ng/mL. Kadar neopterin plasma pada kelompok kontrol  1,50 (SD 0,18) ng/mL, sebelum terapi 1,12 (SD 0,22) ng/mL, bulan kedua 1,08 (SD 0,22) ng/mL, bulan keempat 0,97 (SD 0,35) ng/mL, dan bulan keenam 0,45 (SD 0,29) ng/mL. Kadar neopterin tertinggi didapatkan sebelum terapi yang kemudian menurun secara bertahap sesuai terapi bersamaan dengan perbaikan gejala klinis. Kadar neopterin pada kontrol lebih tinggi dibandingkan pasien selama masa pengamatan. Dapat disimpulkan kadar neopterin plasma mempunyai potensi sebagai biomarker kemajuan terapi tuberkulosis paru anak.
Kata Kunci: Anak, biomarker, neopterin plasma, terapi, tuberkulosis paru
Downloads
References
Cissy BK dan Darfioes B. Tuberkulosis: Epidemologi. Di dalam: Nastiti NR, Bambang S, Darmawan BS, penyunting. Buku Ajar Respirologi Anak edisi 1. Jakarta: Badan Penerbit IDAI; 2008; 162-166.
Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan Republik Indonesia. Strategi Nasional Pengendalian Tb di Indonesia 2010-2014. Jakarta: Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan Republik Indonesia; 2011.
Chandrawati H. Hubungan Body Mass Index dan Laju Endap Darah (LED) pada Penderita Tuberkulosis Paru Sesudah Pengobatan Antituberkulosis 6 bulan. [Tesis]. Universitas Brawijaya, Malang. 2006.
Graham SM, Ahmed T, Amanullah F, et al. Evaluation of Tuberculosis Diagnostics in Children: Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus from an expert panel. The Journal of Infectious Disease. 2012; 205(2): 199-208.
Wallis RS, Pai M, Menzies, D, et al. Biomarkers and Diagnostics: Progress, Need, and Translation Into Practice. The Lancet. 2010; 357(9729): 1920-37.
Murrs,C, Widner B, Wirleitner B, and Fuchs D. Neopterin as a Marker for Immune System Activation. Current Drugs Metabolism. 2002; 3(2): 175-187.
Turgut T, Akbulut H, Deveci F, Kacar C, and Muz MH. Serum Interleukin-2 And Neopterin Levels as Useful Markers for Treatment of Active Pulmonary Tuberculosis. The Tohoku Journal of Experimental Medicine. 2006; 209(4): 321-328.
Yani FF, Machmoed R, Marhefdison, dan Darfioes Basir. Tuberculosis Score Chart Signs And Symptoms In Children With Positive Tuberculin Skin Tests. Paediatrica Indonesiana. 2012; 52(2): 78-85.
Alsagaff H dan Mukty A. Dasar-Dasar Ilmu Penyakit Paru. Surabaya: Airlangga University Press; 2002.
Rom WN and Garay SM. Tuberculosis. 2nd edition. Philadelphia: Lippincot Williams and Wilkins; 2004; p. 251-379.
Juffermans NP, Verbon A, van Deventer SJ, et al. Elevated Chemokine Concentrations in Sera of Human Immunodeficiency Virus (HIV) Seropositive and HIV Seronegativeand Hivseronegative Patiens with Tuberculosis: A Possible Role for Mycrobacterial Lipoarabinomannan. Infection and Immunity. 1999; 67(8): 4295-4297.
Immanuel C, Rajeswari R, and Rahman F. Serial Evaluation of Serum Neopterin in HIV Seronegative Patients Treated for Tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2001; 5(2): 185-190.
Hosp M, Elliot AM, Raynes JG, et al. Neopterin, ß2-Microglobulin, and Acute Phase Protein in HIV-1-Seropositive and Seronegative Zambian Patients with Tuberculosis. Lung. 1997; 175: 265-275.
Plata-Nazar K and Jankowska K. Clinical Usefulness of Determining the Concentration of Neopterin. Pteridines. 2011; 22: 77-89.
Fuchs D, Hausen A, Kofler M, Kosanowski H, Reibnegger G, and Wacther H. Neopterin as an Index of Immune Response in Patients with Patients with Tuberculosis. Lung. 1984; 162: 337-346.
Horak E, Gassner I, Soelder B, WachterH, and Fuchs D. Neopterin Levels and Pulmonary Tuberculosis n Infants. Lung. 1998; 176(5): 337-344.
Ryu JY, Ryu KH, Kim SH, Lee JS, Cheon SH, and Seoh JY. Soluble IL-2R, IFN gamma, and Neopterin as Immunologic Markers in Patients with Tuberculosis. Tuberculosis and Respiratory Disease. 2002; 53(3): 294-308.
Werner E, Bichler A, Daxenbichler G, et al. Determination of Neopterin in Serum and Urine. Clinical Chemistry. 1987; 33(1): 62-66.
Millner MM, Franthal W, Thalhammer G, et al. Neopterin Concentrations in Cerebral Fluid and Serum as an Aid in Differentiating Central Nervous System and Peripheral Infections in Children. Clinical Chemistry. 1998; 44(1): 161-167.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
